modelHaloperidol

Diagram of Haloperidol

Extends from Pharmacolibrary.Drugs.ATC.N.N05AD01.

Information

name:Haloperidol
ATC code:N05AD01
route:oral
compartments:2
dosage:5mg
volume of distribution:18.2L
clearance:0.58L/h/kg
other parameters in model implementation

Haloperidol is a typical antipsychotic medication, primarily used to treat schizophrenia, acute psychosis, and for control of severe behavioral problems in children. It is also used for the management of tics and vocal utterances in Tourette's syndrome. Haloperidol is approved and widely used in clinical practice today.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult male volunteers following single oral dose administration.

References

  1. Franken, LG, et al., & de Winter, BCM (2017). Population pharmacokinetics of haloperidol in terminally ill adult patients. European journal of clinical pharmacology 73(10) 1271–1277. DOI:10.1007/s00228-017-2283-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28681176

  2. Simon, N, et al., & Azorin, JM (2022). Comorbidities and the right dose: antipsychotics. Expert opinion on drug metabolism & toxicology 18(7-8) 507–518. DOI:10.1080/17425255.2022.2113378 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35979611

  3. Midha, KK, et al., & McKay, G (1989). Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. Journal of clinical psychopharmacology 9(2) 98–104. DOI:10.1097/00004714-198904000-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2723140

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)